There is no single “best” injection for osteoporosis. The right choice depends on how severe your bone loss is, whether you’ve already fractured, and what your long-term treatment plan looks like. Injectable osteoporosis medications fall into two categories: bone-building drugs that actively grow new bone, and bone-protecting drugs that slow bone breakdown. For people at very high fracture risk, current guidelines recommend starting with a bone-building injection first, then switching to a bone-protecting one. For moderate osteoporosis, a bone-protecting injection alone is often enough.
Two Types of Injectable Treatments
Bone-protecting injections (called antiresorptive drugs) work by slowing down the cells that break down old bone. This tips the balance toward a net gain in bone density over time, but the gains are gradual. The two main injectable options in this category are denosumab and zoledronic acid.
Bone-building injections (called anabolic drugs) take a different approach. They stimulate the cells that form new bone, producing faster and larger increases in bone density. The injectable options here are teriparatide, abaloparatide, and romosozumab. These are generally reserved for people with severe osteoporosis because they’re more expensive and come with time limits on use.
Denosumab: Every 6 Months in a Clinic
Denosumab is a biologic drug given as an injection under the skin every six months in a healthcare setting. It works by blocking a protein that osteoclasts (bone-destroying cells) need to survive and function. In a large comparative study of nearly half a million postmenopausal women, denosumab reduced the risk of hip fracture by 36% and non-vertebral fractures by 43% compared to the most common oral osteoporosis pill, alendronate. Those benefits grew over time: fracture risk dropped 9% in year one, 12% in year two, and 31% by year five.
Denosumab is typically considered when you can’t tolerate bisphosphonate pills, when you have a T-score of negative 2.5 or lower, or when you have a history of fragility fractures. It’s also an option for people with reduced kidney function who can’t receive zoledronic acid.
One serious drawback: you cannot simply stop denosumab. When treatment is discontinued, bone turnover markers spike within about six months, and bone density can drop back to or even below pre-treatment levels within one to two years. Worse, there’s a significant rebound risk of multiple vertebral fractures. In one review, the median number of vertebral fractures after stopping denosumab was five, typically occurring around 11 months after the last injection. This means that once you start denosumab, you need a clear plan with your doctor for either continuing it long-term or transitioning to another medication.
Zoledronic Acid: Once a Year by IV
Zoledronic acid is a bisphosphonate delivered as a 5 mg intravenous infusion once a year. The infusion takes at least 15 minutes in a clinical setting. It works by binding directly to bone mineral and shutting down the activity of bone-resorbing cells.
The once-yearly schedule makes it appealing for people who have trouble remembering daily or weekly pills, or who can’t tolerate oral bisphosphonates due to stomach issues. Guidelines suggest it as a reasonable choice for patients with a T-score at or below negative 3.0, or for those with fracture history regardless of T-score, provided kidney function is adequate. You need a creatinine clearance above 35 mL/min to safely receive it.
Flu-like symptoms (fever, muscle aches, headache) are common after the first infusion, typically lasting one to three days. Unlike denosumab, zoledronic acid stays bound in bone for years after you stop treatment, so there’s no sharp rebound in fracture risk when it’s discontinued.
Teriparatide and Abaloparatide: Daily Self-Injections
Teriparatide and abaloparatide are bone-building drugs given as daily injections under the skin, similar to how insulin is delivered. You self-administer them at home using a pen device. Both mimic parathyroid hormone to stimulate new bone formation on bone surfaces.
These are reserved for severe osteoporosis: typically a T-score below negative 3.0, multiple vertebral fractures, or situations where bone-protecting drugs haven’t been enough. They produce the largest gains in bone density of any osteoporosis treatment, particularly at the spine.
The critical limitation is time. Cumulative lifetime use of teriparatide and abaloparatide combined is capped at two years. This restriction exists because in animal studies, long-term exposure caused bone tumors in rats. Whether this risk translates to humans isn’t established, but the precaution stands. Once you finish the two-year course, you must transition to a bone-protecting drug to maintain the gains. Without follow-up treatment, bone density drops quickly, especially in postmenopausal women.
Romosozumab: Monthly for One Year
Romosozumab has a unique dual action. It blocks a protein called sclerostin that normally puts the brakes on bone-building cells, so it both increases bone formation and decreases bone breakdown at the same time. It’s given as a monthly injection (two shots per visit) in a clinic for 12 months.
Current guidelines list romosozumab as a first-line option for postmenopausal women at very high fracture risk, particularly those with vertebral fractures. It produces rapid gains in bone density over its one-year treatment window.
The main safety concern is cardiovascular. Romosozumab carries a boxed warning against use in anyone who has had a heart attack or stroke within the past year. If you have significant cardiovascular risk factors, your doctor will weigh that carefully before prescribing it. Like the other bone-building drugs, romosozumab requires a transition to a bone-protecting medication after the 12-month course ends.
Why Treatment Order Matters
For people with severe osteoporosis, starting with a bone-building injection and then switching to a bone-protecting one produces better results than the reverse order. In one well-known study, two years of teriparatide followed by two years of denosumab increased spine bone density by 18.3% and total hip density by 6.6% over four years. These gains were significantly larger than what bisphosphonates achieved after teriparatide.
The reason is straightforward: bone-building drugs create new bone tissue, and bone-protecting drugs lock those gains in place. If you use a bone-protecting drug first and then switch to a bone-building one, the transition is less efficient because the bone-builder has to overcome the suppressed bone turnover left by the first drug. Current clinical guidelines strongly recommend prescribing an antiresorptive drug whenever a course of anabolic therapy is finished.
Who Qualifies for Injectable Treatment
Not everyone with osteoporosis needs an injection. Oral bisphosphonate pills remain the standard first step for most people with a T-score below negative 2.5 or a history of fragility fracture. Injectable treatments enter the picture under specific circumstances:
- You can’t take oral bisphosphonates due to gastrointestinal problems, swallowing difficulties, or an inability to stay upright after taking the pill.
- Your osteoporosis is severe, defined as a T-score at or below negative 3.0, two or more mild vertebral fractures, one or more moderate vertebral fractures, or a hip fracture.
- You’re at very high imminent fracture risk, such as having fractured within the last two years, having a T-score at or below negative 3.5, or taking high-dose glucocorticoids.
- Your kidney function is impaired, which rules out bisphosphonates but still allows denosumab.
Rare but serious side effects of long-term antiresorptive treatment include atypical femur fractures and osteonecrosis of the jaw. Both are uncommon, and the fracture-prevention benefits of treatment far outweigh these risks for most patients. Your treatment history, fracture risk profile, and other health conditions all shape which injection fits your situation best.